British Journal of Haematology最新文献_第9页

Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia. 羟基-胞嘧啶 tRNA 修饰作为白血病病情发展的指标和治疗目标。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-10 DOI: 10.1111/bjh.19873

Xu Chen, Rui-Ze Gong, Liu-Ying Mo, Ya-Ting Cheng, Yu Ma, Yi-Tao Qi, Tong-Meng Yan, Zhi-Hong Jiang

{"title":"Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia.","authors":"Xu Chen, Rui-Ze Gong, Liu-Ying Mo, Ya-Ting Cheng, Yu Ma, Yi-Tao Qi, Tong-Meng Yan, Zhi-Hong Jiang","doi":"10.1111/bjh.19873","DOIUrl":"https://doi.org/10.1111/bjh.19873","url":null,"abstract":"Therapeutic approaches for acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) differ due to distinct diagnostic criteria and treatment strengths. However, reliable biomarkers to differentiate AML from MDS are needed. This study investigated transfer RNA (tRNA) modifications, particularly hydroxy-wybutosine (OHyW), in the transition from MDS to AML. We found a significant decrease in OHyW and its biosynthetic enzyme leucine carboxyl methyltransferase 2 (LCMT2, alias symbol is TYW4) levels in AML compared to MDS. Mass spectrometric analysis revealed distinct tRNA modification patterns, with AML showing decreased OHyW and increased precursor levels, indicating a disrupted biosynthetic pathway. Lower LCMT2 expression correlated with reduced drug sensitivity and limited differentiation potential in AML cell lines. The results highlight the pivotal role of tRNA modifications in the progression from MDS to AML and suggest that targeting LCMT2 may enhance therapeutic outcomes in AML. By understanding these molecular mechanisms, we can develop new diagnostic markers and therapeutic strategies, potentially transforming the clinical management of AML and improving patient outcomes.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142613319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block. 针对白血病中的 RNA 修饰：外显子转录组药物是新宠。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-10 DOI: 10.1111/bjh.19894

Manel Esteller

引用次数: 0

Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism. 小儿骨髓间充质干细胞通过接触无关机制支持急性髓性白血病细胞存活并增强化疗抵抗力。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-10 DOI: 10.1111/bjh.19884

Alison Laing, Ahmed Elmarghany, Arwa A Alghaith, Aya Gouma, Thomas Stevens, Alexander Winton, Jennifer Cassels, Cassie J Clarke, Claire Schwab, Christine J Harrison, Brenda Gibson, Karen Keeshan

引用次数: 0

Genetic predisposition to vaccine-induced immune thrombotic thrombocytopenia. 疫苗诱发免疫性血栓性血小板减少症的遗传易感性。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-10 DOI: 10.1111/bjh.19885

Donald M Arnold, Guillaume Paré, Ishac Nazy

引用次数: 0

Successful combined venetoclax to PD-1 blockade and ruxolitinib for refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis. Venetoclax联合PD-1阻断剂和Ruxolitinib治疗难治性Epstein-Barr病毒相关性嗜血细胞淋巴组织细胞增多症获得成功。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-09 DOI: 10.1111/bjh.19900

Yue Song, Xiaofei Yang, Qian Wu, Mengxing Xue, Fei Zhou, Depei Wu, Suning Chen, Xuefeng He

引用次数: 0

Chronic hepatitis E in a patient after chimeric antigen receptor-T-cell treatment for diffuse large B-cell lymphoma and rapid progression towards decompensated liver cirrhosis. 一名弥漫大 B 细胞淋巴瘤患者在接受嵌合抗原受体-T 细胞治疗后出现慢性戊型肝炎，并迅速发展为肝硬化失代偿期。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-07 DOI: 10.1111/bjh.19892

Michael Schwarz, Behrang Mozayani, Michael Trauner, Albert Friedrich Stättermayer

引用次数: 0

Long-term follow-up of bulky classic Hodgkin lymphoma managed with ABVD and PET-guided RT demonstrates excellent outcomes in PET-negative cases. 对采用 ABVD 和 PET 引导 RT 治疗的巨大典型霍奇金淋巴瘤进行的长期随访显示，PET 阴性病例的疗效极佳。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-07 DOI: 10.1111/bjh.19859

J L Kim, D Villa, R P Tonseth, A S Gerrie, D Wilson, F Benard, C P Venner, B Skinnider, P Farinha, G W Slack, A C Lo, D W Scott, L H Sehn, K J Savage

引用次数: 0

Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes. 在急性淋巴细胞白血病成人患者的诱导治疗过程中延迟使用培加司琼酶可降低高度肝毒性的风险，同时不会对治疗效果产生不利影响。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-06 DOI: 10.1111/bjh.19880

Jose Tinajero, Sharon Xu, Dat Ngo, Shanpeng Li, Joycelynne Palmer, Tina Nguyen, Anthony Stein, Paul Koller, Vaibhav Agrawal, Hoda Pourhassan, Lindsey Murphy, Stephen Forman, Dan Douer, Guido Marcucci, Vinod Pullarkat, Ibrahim Aldoss

{"title":"Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.","authors":"Jose Tinajero, Sharon Xu, Dat Ngo, Shanpeng Li, Joycelynne Palmer, Tina Nguyen, Anthony Stein, Paul Koller, Vaibhav Agrawal, Hoda Pourhassan, Lindsey Murphy, Stephen Forman, Dan Douer, Guido Marcucci, Vinod Pullarkat, Ibrahim Aldoss","doi":"10.1111/bjh.19880","DOIUrl":"https://doi.org/10.1111/bjh.19880","url":null,"abstract":"Pegaspargase is a key drug for the treatment of younger adults with acute lymphoblastic leukaemia (ALL). Pegaspargase-associated hepatotoxicity is most common during induction, and its incidence increases with age and body mass index (BMI). We hypothesized that the delayed administration of pegaspargase during induction is associated with lower risk of hepatotoxicity while retaining efficacy. We retrospectively reviewed 141 adult patients with newly diagnosed ALL who received pegaspargase during induction from November 2013 to February 2024. There were 78 (55.3%) patients who received early pegaspargase (EP) on day 4 and 63 (44.7%) patients who received delayed pegaspargase (DP) on day 15. High-grade hepatotoxicity (grade ≥ 3 transaminitis and/or hyperbilirubinaemia) occurred more frequently in the EP group (p = 0.06). Rates of complete remission and negative minimal residual disease post induction were not different between cohorts. Univariate logistic regression analysis showed that BMI and age significantly predicted an increased risk of high-grade hepatotoxicity while DP was associated with a lower risk (odds ratio = 0.44; p = 0.04). Overall survival and event-free survival were not significantly different between cohorts. Delaying pegaspargase administration from day 4 to day 15 during induction cycle in adults with ALL might reduce the risk of high-grade hepatotoxicity without adversely impacting clinical efficacy outcomes.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hereditary pyropoikilocytosis resulting in artefactual thrombocytosis. 遗传性热核细胞增多症导致假性血小板增多。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-06 DOI: 10.1111/bjh.19868

Maria-Angustias Molina-Arrebola, Maria Morales-Pineda, Barbara J Bain

引用次数: 0

Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study 法国使用泊纳替尼治疗任何阶段CML患者的临床结果--来自TOPASE观察性研究的数据。

IF 5.1 2区医学

British Journal of Haematology Pub Date : 2024-11-06 DOI: 10.1111/bjh.19819

F. Huguet, A. Guerci-Bresler, G. Roth-Guepin, E. Cayssials, B. Slama, A. Santagostino, A. Penot, P. Quittet, P. Cony-Makhoul, A. Saad, J. N. Bastie, M. Hacini, V. Coiteux, M. Uzunov, L. Roy, L. Le Clech, M. Berger, A. M. Agneray, E. Messas, G. Etienne, A. Turhan, F. E. Nicolini, P. Rousselot

{"title":"Clinical outcomes in patients in any phase of CML treated with ponatinib in France—Data from the TOPASE observational study","authors":"F. Huguet, A. Guerci-Bresler, G. Roth-Guepin, E. Cayssials, B. Slama, A. Santagostino, A. Penot, P. Quittet, P. Cony-Makhoul, A. Saad, J. N. Bastie, M. Hacini, V. Coiteux, M. Uzunov, L. Roy, L. Le Clech, M. Berger, A. M. Agneray, E. Messas, G. Etienne, A. Turhan, F. E. Nicolini, P. Rousselot","doi":"10.1111/bjh.19819","DOIUrl":"10.1111/bjh.19819","url":null,"abstract":"The TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real-world setting in France. One hundred and twenty CML patients, 105 in chronic phase (CP), 8 in accelerated phase (AP) and 7 in blastic phase (BP) were included. Fifty-one (49%) of the CP-CML patients were in third line of treatment. The trigger for PON initiation in CP-CML was ‘poor response’ in 67 patients, ‘poor tolerance’ in 28 patients and ‘response enhancement’ in seven patients. The median dose at initiation was 30 mg/day [Q1; Q3 = 15; 30] in CP-CML and 45 mg/day [Q1; Q3 = 30; 45] in AP/BP-CML. Of 98 CP-CML evaluable patients, 72 (73.5%) were considered as responders (MMR) at one time point at least once, especially for those in second line of treatment and/or presenting a T315I mutation. Ninety-six of 120 (80%) patients reported at least one adverse event. An arterial occlusive event (AOE) was reported in 11 patients (9.2%). Thus, these real-life data confirm the potency of ponatinib in resistant or intolerant patients with an acceptable safety profile in non-selected patients.NCT number: NCT04048564.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"205 6","pages":"2295-2304"},"PeriodicalIF":5.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11637719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0